Patents on antivirulence therapies

Table 2 Patents concerning the inhibition of bacterial secretion systems

Patent title	Description	Applicationdate	Inventors	Publicationnumber
Method for screening for inhibitors and activators of type III secretion machinery in Gram-negative bacteria	This invention relates to mutant strains of Gram-negative bacteria that constitutively secrete proteins via the type III secretion machinery and to methods of identifying molecules that are able to activate or inhibit secretion in wild-type strains of Gram-negative bacteria	2001	Demers Brigitte; Sansonetti Philippe; Parsot Claude	US6696249 (B1)
Method of detecting substance inhibiting type III secretion mechanism of bacterium and the function of secretory protein thereof	A method whereby a substance specifically inhibiting the type III secretion mechanism and the function of a type III secretory protein secreted therefrom can be detected in large amounts within a short period of time without depending on any animal infection experiments	2001	Omura Satoshi; Abe Akio	KR1020020086208
Secreted Chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type III secretion pathway of a Gram-negative bacteria	The present invention uses a heterologous secretion system, namely a type III system, to investigate whether some Chlamydia proteins, especially Inc proteins and other proteins exhibiting a similar hydropathy profile, might be secreted and demonstrates that these hybrid proteins are secreted by the type III secretion system of Shigella flexneri	2003	Subtil Agathe; Parsot Claude; Dautry-Varsat Alice	US2004131624 (A1)
Bacterial system for protein transport in eukaryotic cells	Development of a system for the targeted transport of proteins into eukaryotic cells by using a type III secretion system and bacteria strains that are mutated in hpaB or homogenous genes. The inventive bacterial system is used to transport bacterial proteins into eukaryotic cells, in order to influence or modify cellular processes such as gene expression, growth, development and defence/resistance mechanisms	2005	Bonas Ulla; Buettner Daniela	WO2005085417 (A2)
Methods of identifying modulators of bacterial type III protein secretion system	Provides methods for identifying inhibitors or activators of bacterial type III protein secretion system by using a recombinant beta-lactamase that can be secreted by a type III protein secretion system. The assay could be easily adapted to a high throughput mode to allow daily screening of several tens of thousands compounds	2005	Goldschmidt Raul; Loeloff Michael	WO2005113791 (A2)
Pharmaceutical composition for the treatment of bacterial infections and sepsis	The invention involves a pharmaceutical composition comprising at least one glycogen synthase kinase 3 β; inhibitor, at least one Rho-kinase inhibitor, and an optional adequate pharmaceutical carrier for producing a drug for the preventive or therapeutic treatment of bacterial infectious diseases by synergistically increasing synthesis and secretion of type II. A secretory phospholipase A2 into the bloodstream so as to boost the body's inherent resistance to infections	2005	Menschikowski Mario; Hagelgans Albert; Siegert Gabriele	WO2005120475
Pyridone compounds as inhibitors of bacterial type III protein secretion systems	Provides compounds that inhibit type III protein secretion useful for the treatment and prevention of bacterial infections, particularly those caused by Gram-negative bacteria, and methods for their use	2005	Li Xiaobing	US2005256137 (A1)
Methods for stimulating an immune response using bacterial antigen delivery system	Provides methods for stimulating and/or increasing an immune response against tumor antigens through the use of the type III secretion system of bacteria. The invention also relates to the preparation of antigen presenting cells from peripheral blood mononuclear cells by using bacteria with a type III secretion system	2006	Old Lloyd J; Ritter Gerd; Nishikawa Hiroyoshi; Gnjatic Sacha; Galan Jorge E	US2009324651 (A1)
Screening system for inhibitors and activators of type III secretion machinery in Gram-negative bacteria	Provides a screening system (comprising inhibitors and activators of type III secretion machinery) that directly transfers pathogenic proteins of Gram-negative bacteria into a host cell to identify substances capable of activating or inhibiting the secretion of type III protein secretion system	2006	Hwang In Gyu; Moon Jae Sun; Kim Sung Uk	KR20080051240 (A)
Application of bovine lactoferrin for preparing a medicinal agent for inhibition of bacteria growth	The invention refers to a new application of bovine lactoferrin for preparing a medicinal agent for inhibiting bacteria growth. The bovine lactoferrin inhibits the growth of bacterial pathogens expressing the type III secretory system	2007	Makmakhon Robert Dzh; Kliari Tomas; Ochoa Tereza	RU2007140789 (A)
Bacterial secretion system and uses	-	2007	Gey Van Pittius Nicolaas Claudius; Warren Robin Mark; Van Helden Paul David	ZA200706520 (A)
Biopolymer and protein production using type III secretion systems of Gram-negative bacteria	Provides proteins, polynucleotide, expression cassette, vector and bacterium compositions for obtaining proteins of interest by expression of same in Gram-negative bacteria with a type III secretion system. Also provides uses for the proteins obtained in the manufacture of isolated proteins and pharmaceutical compositions	2007	Voigt Christopher Ashby; Widmaier Daniel Matthew	WO2008019183 (A2)
Use of the Pseudomonas syringae effector protein HopU1 related to its ability to ADP-ribosylate eukaryotic RNA binding proteins	The invention provides novel methods for modulation of the innate immune response of a plant to infection caused by Pseudomonas syringae, which injects effector proteins into host cells via a type III protein secretion system. Also provides methods for enhancing or suppressing the innate immune response of the plant	2007	Alfano James R; Fu Zheng Qing; Elthon Thomas E	WO2008042026 (A2)
Method and means for preventing and inhibiting type III secretion in infections caused by Gram-negative bacteria	Discloses a means of decreasing bacterial virulence in a mammal or in a plant by inhibition of the type III secretion system at concentrations that do not prevent or substantially reduce bacterial growth. Also disclosed are a therapeutic method and a pharmaceutical composition	2008	Elofsson Mikael	US2010099674 (A1)
Carboplatin compound inhibiting secretion system of phytopathogenic Gram-negative bacteria and biocontrol agent of plant diseases with this compound	Provides an agent for preventing plant diseases, containing carboplatin compounds, to selectively suppress secretion system related to plant pathogenicity	2009	-	KR20110048335 (A)
Inhibition of quorum sensing-mediated processes in bacteria	Provides methods for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production	2009	Bassler Bonnie; Swem Lee	US2011123586 (A1)
Type III secretion inhibitors, analogs and uses thereof	The invention relates to compounds and compositions useful for inhibiting type III secretion systems in pathogenic bacteria, such as Yersinia pestis, and uses of such inhibitors in the treatment and prevention of disease	2009	Goguen Jon; Pan Ning; Lee Kyungae	US2011034463 (A1)
5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection1	Provides a method for inhibiting Gram-negative bacterial pathogenesis, a method of screening for compounds that inhibit type III secretion in Gram-negative bacteria, and compounds that inhibit type III secretion in Gram-negative bacteria	2010	Felise Heather B; Miller Samuel I; Kline Toni	US2011039849 (A1)
Methods for Identifying Inhibitors of the type III Secretion System1	Provides a method for determining whether a test compound can inhibit the function of the type III secretion system. The method identifies drug candidates that are highly specific anti-bacterial agents for treating diseases caused by Gram-negative bacteria with a T3SS	2010	Marlovits Thomas C; Radics Julia; Schmied Wolfgang	US2013130283 (A1)
Attenuated Salmonella inducible secretory expression oral vaccine presentation system and application there of1	The invention comprises an attenuated salmonella inducible secretory expression oral vaccine presentation system containing an antigen expression carrier. The system is controlled by a promoter induced by a microenvironment in an antigen presenting cell and excreted by induction of a bacteria excretion signal, and it uses the attenuated salmonella as the host of the antigen expression carrier	2011	Zichun Hua; Guo Chen	CN102335421 (A)
Bacterial mediated delivery of nuclear protein into pluripotent and differentiated cells1	A modified Pseudomonas aeruginosa type III secretion system has been developed that efficiently delivers selected proteins into a host cell	2011	Jin Shouguang; Bichsel Candace	WO2012012605 (A2)
Inhibitors of bacterial type III secretion system1	Discloses organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems. These inhibitor compounds are useful for combating infections by Gram-negative bacteria with such type III secretion systems	2012	Moir Donald T.; Aiello Daniel; Peet Norton P; Williams John D; Torhan Matthew	US2014142134 (A1)

¹Those published from 2010 onwards are highlighted.